Immunohistochemistry for O 6 -methylguanin-DNA methyltransferase in glioblastomas defined by WHO2016: Correlation with promoter methylation status and patients’ progression-free survival with the cut-off value determined by ROC analysis
作者: Eriel Sandika PareiraYuki KitanoKentaro OharaTokunori KanazawaYu NakagawaKazunari YoshidaHikaru Sasaki
作者单位: 1Department of Neurosurgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan
2Department of Pathology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan
刊名: Journal of Clinical Neuroscience, 2020, Vol.73 , pp.231-236
来源数据库: Elsevier Journal
DOI: 10.1016/j.jocn.2020.01.088
关键词: MGMTMethylationImmunohistochemistryPFSGlioblastoma
原始语种摘要: Abstract(#br)Although promoter methylation status is known to correlate with response to alkylating agents, immunohistochemistry (IHC) is the only available method for MGMT status in many institutions. However, the clinical utility of MGMT IHC is controversial. A hundred and twenty four cases of primary glioblastoma diagnosed by morphology-based criteria over 2 decades were re-appraised based on WHO 2016 classification. Tumor MGMT status was evaluated by IHC and methylation-specific PCR (MSP) to see if any correlation between the results of the 2 methods. The association with patients’ prognoses was also investigated. Among 124 cases, 116 were confirmed to be glioblastoma by definition of WHO2016, and median overall survival (OS) of glioblastoma, IDH-wildtype and epithelioid glioblastoma...
全文获取路径: Elsevier  (合作)
分享到:
来源刊物:
影响因子:1.253 (2012)

×
关键词翻译
关键词翻译
  • survival 生存
  • methylation 甲基化酌
  • promoter 催化剂
  • status 状态
  • analysis 分析
  • progression 级数
  • value 
  • WHO World Health Organization
  • DNA Deoxyribonucleic Acid
  • defined 定义